论文部分内容阅读
目的:观察脑出血患者采用凉血散瘀汤联合依达拉奉治疗后患者神经功能缺损及骨桥蛋白表达变化情况,为临床应用提供依据。方法:将我院收治的100例脑出血患者随机分为观察组和对照组,对照组采用依达拉奉进行干预,观察组患者在对照组基础上联合使用凉血散瘀汤进行治疗。结果:治疗后两组患者NIHSS评分均显著降低(P<0.05),且观察组患者NIHSS评分显著低于对照组(P<0.05);观察组患者临床疗效明显优于对照组,且差异存统计学意义(P<0.05);治疗后两组患者BI指数均显著升高(P<0.05),且观察组患者BI指数显著高于对照组(P<0.05);治疗后两组患者骨桥蛋白水平均显著降低(P<0.05),且观察组患者骨桥蛋白水平显著低于对照组(P<0.05)。结论:凉血散瘀汤联合依达拉奉可有效改善脑出血患者神经功能缺损情况,并降低血清中骨桥蛋白表达情况,具有较高的临床应用价值。
OBJECTIVE: To observe the changes of neurological deficits and osteopontin expression in patients with cerebral hemorrhage treated with Liangxuesanyu Decoction combined with edaravone, and provide basis for clinical application. Methods: 100 cases of cerebral hemorrhage admitted to our hospital were randomly divided into observation group and control group. The control group was treated with edaravone. The observation group was treated with Liangxuesanyu Decoction on the basis of control group. Results: After treatment, the NIHSS scores of the two groups were significantly decreased (P <0.05), and the NIHSS scores of the observation group were significantly lower than those of the control group (P <0.05). The clinical efficacy of the observation group was significantly better than that of the control group (P <0.05). After treatment, the BI index of both groups were significantly increased (P <0.05), and the BI index in the observation group was significantly higher than that of the control group (P <0.05). After treatment, the osteopontin (P <0.05), and the osteopontin level in the observation group was significantly lower than that in the control group (P <0.05). Conclusion: Liangxuesanyu Decoction combined with edaravone can effectively improve the neurological deficits in patients with cerebral hemorrhage and reduce the expression of osteopontin in serum, which has a high clinical value.